We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PROPORTION OF METABOLIC SYNDROME COMPONENTS IN CONFIRMED PANCREATIC ADENOCARCINOMA USING EUS-FNA.
- Authors
Tanțău, Alina; Zaharie, Teodor; Mandrutiu, Alina
- Abstract
Introduction. Metabolic syndrome is a complex interplay between several conditions. Recent data have showed an association between metabolic syndrome and several cancer. The aim of our study was to evaluate the prevalence of metabolic syndrome components in patients with the pancreatic adenocarcinoma. Material and Methods. We have retrospectively identified from the hospital database all patients with focal pancreatic tumors who underwent endoscopic ultrasound (EUS) with guided fine needle aspiration biopsy (EUS-FNA) between July 2019 and November 2020. The patients with pancreatic adenocarcinoma confirmed by pathological examination of tissue obtained by EUS-FNA or further curative resection were included in study. Demographics, anthropometric measurements, data on metabolic syndrome, clinical history of diabetes, hypertension, pancreatic and liver disease, blood levels of glucose, cholesterol, triglycerides were collected from the medical charts and analyzed. Results. A total of 51 patients, 24 men and 27 women with a median age of 63,76 (32-79 years) had pancreatic adenocarcinoma histologically confirmed an d were included in the study. Twenty four patients (47,05%) had increased waist circumference with a body mass index (BMI) greater than 25kg/m2. The fasting blood glucose concentration > 100 mg/dL was found in 35 cases (68,62%), 18 patients were previous diagnosed with type 2 diabetes mellitus (median age of diagnostic 57,33 years). Nineteen patients (37,25%) were treated for heart disease and arterial hypertension. An increased level of triglycerides >150 mg/dL was found in 9 patients (19,64)%, three of them were on therapy for dyslipidemia. Fourteen patients (27,45%) had liver steatosis diagnosed by abdominal ultrasound. Conclusions. Although this is an observational retrospective study, the metabolic syndrome components are frequent in our group. Some metabolic syndrome components as overweight or obesity and diabetes mellitus, represents risk factors for pancreatic adenocarcinoma. In these category of patients, searching and aggressively treating is a good strategy in order to decrease the morbidity and the mortality of patients with pancreatic cancer.
- Subjects
DYSLIPIDEMIA; PANCREATIC tumors; METABOLIC syndrome; TYPE 2 diabetes; NEEDLE biopsy; PANCREATIC diseases; CANCER-related mortality
- Publication
Journal of Gastrointestinal & Liver Diseases, 2023, Vol 32, p17
- ISSN
1841-8724
- Publication type
Article